Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

QCLS US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

QCLS US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Q/c Technologies, Inc.(QCLS US)

$0.31+0.000.36%Ext:$0.29-0.025.01%(After Hours · 23:00:00 UTC)
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Q/c Technologies, Inc.(QCLS US)

$0.31+0.000.36%Ext:$0.29-0.025.01%(After Hours · 23:00:00 UTC)
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Financials & Metrics

FinancialsChartingShort InterestEmployees

Q/c Technologies, Inc. — Company Profile

Q/C Technologies, Inc. focuses its efforts on pioneering advanced quantum-class photonic computing and developing robust blockchain infrastructure. The company possesses the sole worldwide rights to LightSolver's revolutionary Light-speed Laser Processing Unit (LPU). This innovative optical and laser-driven computing system is engineered specifically for applications within the cryptocurrency sector, offering a substantial energy efficiency improvement of up to 90% while simultaneously outperforming both conventional GPUs and even quantum computing systems.

Sector
Health Care
Industry
Pharmaceuticals
Exchange
UQ
CEO
Joshua N. Silverman
Headquarters
New York, NY, US
IPO Date
Jan 23, 2014
Employees
3
Website
www.qctechnologies.com

Key Metrics

Price
$0.75
Market Cap
$6.13M
Revenue (TTM)
$0.00
Net Income (TTM)
$-1242777.00
EPS (TTM)
-0.19
P/E (TTM)
-0.52
P/B (TTM)
0.26
Dividend Yield
0.00%
ROE (TTM)
-5.25%
ROA (TTM)
-3.25%
Operating Margin
0.00%
Beta
1.72

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Q/C Technologies, Inc. focuses its efforts on pioneering advanced quantum-class photonic computing and developing robust blockchain infrastructure. The company possesses the sole worldwide rights to LightSolver's revolutionary Light-speed Laser Processing Unit (LPU). This innovative optical and laser-driven computing system is engineered specifically for applications within the cryptocurrency sector, offering a substantial energy efficiency improvement of up to 90% while simultaneously outperforming both conventional GPUs and even quantum computing systems.

Website
www.qctechnologies.com
Location
New York, NY, US
Phone856 848 8698
Employees3
CEOJoshua N. Silverman
Sector
Health Care
Industry
Pharmaceuticals
IPO DateJan 23, 2014

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(578)

Expand
  • 8-KNotice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing05:00PM
  • Form 4Silverman Joshua2 Oct
  • Form 4/ASilverman Joshua2 Oct
  • Form 3Ehrlichman Yossef22 Sep
  • 8-KEntry into a Material Definitive Agreement18 Sep
  • 8-KTermination of a Material Definitive Agreement11 Sep
  • Form 3Fagan Charles Todd17 Aug
  • 10-QQ2ended 30 Jun 202612 Aug
  • 8-KTermination of a Material Definitive Agreement2 Jul
  • 10-QQ1ended 31 Mar 202615 May
  • Form 4Voss Chelsea Sierra14 May
  • 10-K/AFY 2025ended 31 Dec 202529 Apr
  • Form 4Friscia Stephen15 Apr
  • Form 4Voss Chelsea Sierra15 Apr
  • Form 4Glass Mitchell15 Apr
  • Form 4White Billy Joe15 Apr
  • Form 4Bernstein Bruce15 Apr
  • Form 4Silverman Joshua15 Apr
  • 10-KFY 2025ended 31 Dec 202515 Apr
  • NT 10-KFY 2025ended 31 Dec 202531 Mar

News

  • Q/C Technologies Announces Research Collaboration with Sandia National Laboratories, a $5 Billion U.S. Department of Energy Lab1 Oct
  • Q/C Technologies Announces Research Collaboration with Sandia National Laboratories, a $5 Billion U.S. Department of Energy Lab30 Sep
  • Q/C Technologies Names Yossef Ehrlichman Chief Technology Officer to Lead Optical Processor Development15 Sep

Mentions in Filings

  • … tors of Xwell, Inc. (Formerly XpresSpa Holdings, Inc.) the leading airport spa company in the world, based in New York, serves as a Director for Neurotrope since November 14, 2016, Petros Pharmaceuticals, Inc. and <strong>Q/C Technologies, Inc.</strong> Mr. Bernstein holds a Bachelor of Business Administration from City University of New York (Baruch). The Board believes that Mr. Bernstein’s experience in finance, audit, capital markets and in advising public co …
    WRAP TECHNOLOGIES, INC.Q/c Technologies, Inc.·DEF 14A - Definitive proxy statement·Q4 26·6 Nov
  • … rs of Xwell, Inc. (Formerly XpresSpa Holdings, Inc.) the leading airport spa company in the world, based in New York, serves as a Director for Neurotrope since November 14, 2016, Petros Pharmaceuticals, Inc. and <strong>Q/C Technologies, Inc.</strong> Mr. Bernstein holds a Bachelor of Business Administration from City University of New York (Baruch). The Board believes that Mr. Bernstein’s experience in finance, audit, capital markets and in advising public …
    WRAP TECHNOLOGIES, INC.Q/c Technologies, Inc.·ARS - Annual report to security holders·FY25·6 Nov
  • … tors of Xwell, Inc. (Formerly XpresSpa Holdings, Inc.) the leading airport spa company in the world, based in New York, serves as a Director for Neurotrope since November 14, 2016, Petros Pharmaceuticals, Inc. and <strong>Q/C Technologies, Inc.</strong> Mr. Bernstein holds a Bachelor of Business Administration from City University of New York (Baruch). The Board believes that Mr. Bernstein’s experience in finance, audit, capital markets and in advising public co …
    WRAP TECHNOLOGIES, INC.Q/c Technologies, Inc.·PRER14A - Preliminary proxy statement (revision)·Q4 26·26 Oct
  • … tors of Xwell, Inc. (Formerly XpresSpa Holdings, Inc.) the leading airport spa company in the world, based in New York, serves as a Director for Neurotrope since November 14, 2016, Petros Pharmaceuticals, Inc. and <strong>Q/C Technologies, Inc.</strong> Mr. Bernstein holds a Bachelor of Business Administration from City University of New York (Baruch). The Board believes that Mr. Bernstein’s experience in finance, audit, capital markets and in advising public co …
    WRAP TECHNOLOGIES, INC.Q/c Technologies, Inc.·PRE 14A - Preliminary proxy statement·Q4 26·16 Oct
  • … recurring basis using Level 1 inputs, which are based on unadjusted quoted market prices within active markets. There have been no changes in valuation approaches or techniques and related inputs. **INVESTMENT IN <strong>Q/C TECHNOLOGIES, INC.</strong>** *Series G Preferred Shares and Warrants* On May 20, 2024, the Company entered into a Securities Purchase Agreement (the “Series G SPA”) with a public company operating in the medical industry, MyMD Pharmaceuti …
    PharmaCyte Biotech, Inc.Q/c Technologies, Inc.·10-Q - Quarterly report Q1·Q1 27·14 Sep
  • #\*Prothena Corp. PLC 164,759 1,451,527 \*PTC Therapeutics, Inc. 153,642 11,604,580 \*Puma Biotechnology, Inc. 153,101 992,094 \*Pyxis Oncology, Inc. 18,887 27,386 \*Q/C Technologies, Inc. 5,569 23,334 \*Quanterix Corp. 131,770 835,422 \*QuidelOrtho Corp. 212,164 5,764,496 \*Quipt Home Medical Corp. 34,007 121,405 \*RadNet, Inc. 211,321 14,813,602
    Dimensional ETF TrustQ/c Technologies, Inc.·NPORT-EX - NT NPORT-P - Notification of late filing (portfolio holdings)·Q1 26·13 Aug

Key Stats

Trading

Px/Chg 1D$0.75 / -3.52%
Avg Volume574.31K
Beta1.72
Mkt Cap6.13M
FD Mkt Cap4.02M

Float

Shrs Out/Float8.19M / 8.11M
Short Float0.93%
Days to Cover5.99
Stock Repurchased$0.00

Current Valuation

EV8.12M
EV/EBITDA-0.90
EV/Sales0.00
P/B0.26
P/S0.00
FCF Yield-53.65%
ROE-5.25%
ROA-3.25%
Current Ratio3.71

Estimates

P/E-0.52
Est P/E0.00
Est EPS0.00
Est PEG0.00

Valuation

Metric5Yr AvgMar '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-4.58-4.23-4.93
Price / Sales0.000.000.00
Price / Book Value0.701.150.26
Price / Free Cash Flow-4.83-7.79-1.86
ENTERPRISE VALUE METRICS
Enterprise Value16.124.18.1
Enterprise Value / Sales0.000.000.00
Enterprise Value / EBITDA-5.31-4.08-6.53
Enterprise Value / EBIT-5.31-4.08-6.53

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue—-----
Gross Income—-----
EBITDA-20.6%-29.3-15.3-16.4-8.7-11.6
EBIT-20.6%-29.3-15.3-16.4-8.7-11.6
Net Income-21%-29.9-15.2-4.0-23.4-11.6
EPS (Diluted)-75.9%-2,560.65-1,174.26-532.80-1,114.54-8.66
BALANCE SHEET
Cash & ST Inv8.1%11.64.84.98.515.8
Total Assets13.5%24.817.517.921.441.2
Total Liabilities102%1.22.85.16.719.4
Total Shareholder Equity-2.1%23.614.712.814.721.8
CASH FLOW
Net Operating Cash Flow-17.4%-19.5-12.3-13.0-9.0-9.1
Cap Ex—-----2.0
Free Cash Flow-13.2%-19.5-12.3-13.0-9.0-11.1

Enterprise Value Bridge

Millions USD13 Nov '26
Price (As of 13 Nov '26)0.32
Basic Shares8.19
Market Cap2.6
Diluted Shares8.24
Fully Diluted Shares Outstanding8.24
Fully Diluted Market Cap2.6
+Consolidated Debt0.4
−In-the-Money Convertible Debt—
+Capital Leases0.4
+Operating Leases—
−Cash & Equivalents-0.3
−Short-term Investments-10.7
+Total Preferred3.1
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value5.8

Related companies

Eli Lilly and Company

LLY US

Johnson & Johnson

JNJ US

AbbVie Inc.

ABBV US

Merck & Co., Inc.

MRK US

Novartis Ag

NVS US

Astrazeneca Plc

AZN US

Abbott Laboratories

ABT US

Novo Nordisk A/S

NVO US

Pfizer Inc

PFE US

Vertex Pharmaceuticals Inc / Ma

VRTX US

Bristol Myers Squibb Company

BMY US

Csl Ltd

CSLLY US

Q/c Technologies, Inc. — Company Profile

Q/C Technologies, Inc. focuses its efforts on pioneering advanced quantum-class photonic computing and developing robust blockchain infrastructure. The company possesses the sole worldwide rights to LightSolver's revolutionary Light-speed Laser Processing Unit (LPU). This innovative optical and laser-driven computing system is engineered specifically for applications within the cryptocurrency sector, offering a substantial energy efficiency improvement of up to 90% while simultaneously outperforming both conventional GPUs and even quantum computing systems.

Sector
Health Care
Industry
Pharmaceuticals
Exchange
UQ
CEO
Joshua N. Silverman
Headquarters
New York, NY, US
IPO Date
Jan 23, 2014
Employees
3
Website
www.qctechnologies.com

Key Metrics

Price
$0.75
Market Cap
$6.13M
Revenue (TTM)
$0.00
Net Income (TTM)
$-1242777.00
EPS (TTM)
-0.19
P/E (TTM)
-0.52
P/B (TTM)
0.26
Dividend Yield
0.00%
ROE (TTM)
-5.25%
ROA (TTM)
-3.25%
Operating Margin
0.00%
Beta
1.72

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Q/C Technologies, Inc. focuses its efforts on pioneering advanced quantum-class photonic computing and developing robust blockchain infrastructure. The company possesses the sole worldwide rights to LightSolver's revolutionary Light-speed Laser Processing Unit (LPU). This innovative optical and laser-driven computing system is engineered specifically for applications within the cryptocurrency sector, offering a substantial energy efficiency improvement of up to 90% while simultaneously outperforming both conventional GPUs and even quantum computing systems.

Website
www.qctechnologies.com
Location
New York, NY, US
Phone856 848 8698
Employees3
CEOJoshua N. Silverman
Sector
Health Care
Industry
Pharmaceuticals
IPO DateJan 23, 2014

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(578)

Expand
  • 8-KNotice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing05:00PM
  • Form 4Silverman Joshua2 Oct
  • Form 4/ASilverman Joshua2 Oct
  • Form 3Ehrlichman Yossef22 Sep
  • 8-KEntry into a Material Definitive Agreement18 Sep
  • 8-KTermination of a Material Definitive Agreement11 Sep
  • Form 3Fagan Charles Todd17 Aug
  • 10-QQ2ended 30 Jun 202612 Aug
  • 8-KTermination of a Material Definitive Agreement2 Jul
  • 10-QQ1ended 31 Mar 202615 May
  • Form 4Voss Chelsea Sierra14 May
  • 10-K/AFY 2025ended 31 Dec 202529 Apr
  • Form 4Friscia Stephen15 Apr
  • Form 4Voss Chelsea Sierra15 Apr
  • Form 4Glass Mitchell15 Apr
  • Form 4White Billy Joe15 Apr
  • Form 4Bernstein Bruce15 Apr
  • Form 4Silverman Joshua15 Apr
  • 10-KFY 2025ended 31 Dec 202515 Apr
  • NT 10-KFY 2025ended 31 Dec 202531 Mar

News

  • Q/C Technologies Announces Research Collaboration with Sandia National Laboratories, a $5 Billion U.S. Department of Energy Lab1 Oct
  • Q/C Technologies Announces Research Collaboration with Sandia National Laboratories, a $5 Billion U.S. Department of Energy Lab30 Sep
  • Q/C Technologies Names Yossef Ehrlichman Chief Technology Officer to Lead Optical Processor Development15 Sep

Mentions in Filings

  • … tors of Xwell, Inc. (Formerly XpresSpa Holdings, Inc.) the leading airport spa company in the world, based in New York, serves as a Director for Neurotrope since November 14, 2016, Petros Pharmaceuticals, Inc. and <strong>Q/C Technologies, Inc.</strong> Mr. Bernstein holds a Bachelor of Business Administration from City University of New York (Baruch). The Board believes that Mr. Bernstein’s experience in finance, audit, capital markets and in advising public co …
    WRAP TECHNOLOGIES, INC.Q/c Technologies, Inc.·DEF 14A - Definitive proxy statement·Q4 26·6 Nov
  • … rs of Xwell, Inc. (Formerly XpresSpa Holdings, Inc.) the leading airport spa company in the world, based in New York, serves as a Director for Neurotrope since November 14, 2016, Petros Pharmaceuticals, Inc. and <strong>Q/C Technologies, Inc.</strong> Mr. Bernstein holds a Bachelor of Business Administration from City University of New York (Baruch). The Board believes that Mr. Bernstein’s experience in finance, audit, capital markets and in advising public …
    WRAP TECHNOLOGIES, INC.Q/c Technologies, Inc.·ARS - Annual report to security holders·FY25·6 Nov
  • … tors of Xwell, Inc. (Formerly XpresSpa Holdings, Inc.) the leading airport spa company in the world, based in New York, serves as a Director for Neurotrope since November 14, 2016, Petros Pharmaceuticals, Inc. and <strong>Q/C Technologies, Inc.</strong> Mr. Bernstein holds a Bachelor of Business Administration from City University of New York (Baruch). The Board believes that Mr. Bernstein’s experience in finance, audit, capital markets and in advising public co …
    WRAP TECHNOLOGIES, INC.Q/c Technologies, Inc.·PRER14A - Preliminary proxy statement (revision)·Q4 26·26 Oct
  • … tors of Xwell, Inc. (Formerly XpresSpa Holdings, Inc.) the leading airport spa company in the world, based in New York, serves as a Director for Neurotrope since November 14, 2016, Petros Pharmaceuticals, Inc. and <strong>Q/C Technologies, Inc.</strong> Mr. Bernstein holds a Bachelor of Business Administration from City University of New York (Baruch). The Board believes that Mr. Bernstein’s experience in finance, audit, capital markets and in advising public co …
    WRAP TECHNOLOGIES, INC.Q/c Technologies, Inc.·PRE 14A - Preliminary proxy statement·Q4 26·16 Oct
  • … recurring basis using Level 1 inputs, which are based on unadjusted quoted market prices within active markets. There have been no changes in valuation approaches or techniques and related inputs. **INVESTMENT IN <strong>Q/C TECHNOLOGIES, INC.</strong>** *Series G Preferred Shares and Warrants* On May 20, 2024, the Company entered into a Securities Purchase Agreement (the “Series G SPA”) with a public company operating in the medical industry, MyMD Pharmaceuti …
    PharmaCyte Biotech, Inc.Q/c Technologies, Inc.·10-Q - Quarterly report Q1·Q1 27·14 Sep
  • #\*Prothena Corp. PLC 164,759 1,451,527 \*PTC Therapeutics, Inc. 153,642 11,604,580 \*Puma Biotechnology, Inc. 153,101 992,094 \*Pyxis Oncology, Inc. 18,887 27,386 \*Q/C Technologies, Inc. 5,569 23,334 \*Quanterix Corp. 131,770 835,422 \*QuidelOrtho Corp. 212,164 5,764,496 \*Quipt Home Medical Corp. 34,007 121,405 \*RadNet, Inc. 211,321 14,813,602
    Dimensional ETF TrustQ/c Technologies, Inc.·NPORT-EX - NT NPORT-P - Notification of late filing (portfolio holdings)·Q1 26·13 Aug

Key Stats

Trading

Px/Chg 1D$0.75 / -3.52%
Avg Volume574.31K
Beta1.72
Mkt Cap6.13M
FD Mkt Cap4.02M

Float

Shrs Out/Float8.19M / 8.11M
Short Float0.93%
Days to Cover5.99
Stock Repurchased$0.00

Current Valuation

EV8.12M
EV/EBITDA-0.90
EV/Sales0.00
P/B0.26
P/S0.00
FCF Yield-53.65%
ROE-5.25%
ROA-3.25%
Current Ratio3.71

Estimates

P/E-0.52
Est P/E0.00
Est EPS0.00
Est PEG0.00

Valuation

Metric5Yr AvgMar '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-4.58-4.23-4.93
Price / Sales0.000.000.00
Price / Book Value0.701.150.26
Price / Free Cash Flow-4.83-7.79-1.86
ENTERPRISE VALUE METRICS
Enterprise Value16.124.18.1
Enterprise Value / Sales0.000.000.00
Enterprise Value / EBITDA-5.31-4.08-6.53
Enterprise Value / EBIT-5.31-4.08-6.53

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue—-----
Gross Income—-----
EBITDA-20.6%-29.3-15.3-16.4-8.7-11.6
EBIT-20.6%-29.3-15.3-16.4-8.7-11.6
Net Income-21%-29.9-15.2-4.0-23.4-11.6
EPS (Diluted)-75.9%-2,560.65-1,174.26-532.80-1,114.54-8.66
BALANCE SHEET
Cash & ST Inv8.1%11.64.84.98.515.8
Total Assets13.5%24.817.517.921.441.2
Total Liabilities102%1.22.85.16.719.4
Total Shareholder Equity-2.1%23.614.712.814.721.8
CASH FLOW
Net Operating Cash Flow-17.4%-19.5-12.3-13.0-9.0-9.1
Cap Ex—-----2.0
Free Cash Flow-13.2%-19.5-12.3-13.0-9.0-11.1

Enterprise Value Bridge

Millions USD13 Nov '26
Price (As of 13 Nov '26)0.32
Basic Shares8.19
Market Cap2.6
Diluted Shares8.24
Fully Diluted Shares Outstanding8.24
Fully Diluted Market Cap2.6
+Consolidated Debt0.4
−In-the-Money Convertible Debt—
+Capital Leases0.4
+Operating Leases—
−Cash & Equivalents-0.3
−Short-term Investments-10.7
+Total Preferred3.1
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value5.8

Related companies

Eli Lilly and Company

LLY US

Johnson & Johnson

JNJ US

AbbVie Inc.

ABBV US

Merck & Co., Inc.

MRK US

Novartis Ag

NVS US

Astrazeneca Plc

AZN US

Abbott Laboratories

ABT US

Novo Nordisk A/S

NVO US

Pfizer Inc

PFE US

Vertex Pharmaceuticals Inc / Ma

VRTX US

Bristol Myers Squibb Company

BMY US

Csl Ltd

CSLLY US